ClinicalTrials.gg

Program

diacerein

Also written as “Diacerein”, “diacerein 1% ointment” and “AC-201”.

Its studies are mostly in Osteoarthritis, Knee · Epidermolysis Bullosa Simplex · Epidermolysis Bullosa · Psoriasis · Gout, led by 7 companies.

Furthest: phase 4, since May 10, 201721 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Castle Creek Pharmaceuticals70 open or runningphase 2since May 10, 2017May 10, 2017none ahead
TWi Biotechnology61 open or runningphase 3since Sep 12, 2023Jan 11, 2011none ahead
Wockhardt30 open or runningphase 4since Feb 26, 2007Feb 26, 2007none ahead
TRB Chemedica21 open or runningphase 3since Mar 16, 2020Jun 28, 2010Dec 31, 2026phase 3 · NCT04318041
Accro Bioscience (Suzhou)10 open or runningphase 2since May 7, 2025May 7, 2025none ahead
ANS Pharma10 open or runningphase 2since Jun 27, 2017Jun 27, 2017none ahead
TRB Chemedica International10 open or runningphase 3since Feb 10, 2016Feb 10, 2016none ahead

Also a collaborator on its studies: arthrolab-inc and tkl-research-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Feb 26, 2007.

  1. Jan 11, 2011TWi Biotechnology's first study: phase 2 study in Diabetes Mellitus, Type 2New to TWi BiotechnologyTWi Biotechnology · NCT01276106 · 259 enrolled · United States, Taiwan
  2. Oct 19, 2012Phase 2 study in HyperuricemiaTWi Biotechnology · NCT01712204 · 82 enrolled · Taiwan
  3. Nov 6, 2014Phase 2 study in GoutTWi Biotechnology · NCT02287818 · 127 enrolled · Taiwan
  4. Feb 10, 2016TRB Chemedica International's first study: phase 3 study in OsteoarthritisNew to TRB Chemedica InternationalTRB Chemedica International · NCT02688400 · 380 enrolled · Austria, Belgium, Canada and more
  5. May 10, 2017Castle Creek Pharmaceuticals's first study: phase 2 study in Epidermolysis Bullosa SimplexNew to Castle Creek PharmaceuticalsCastle Creek Pharmaceuticals · NCT03154333 · 54 enrolled · United States, Australia, Austria and more
  6. Jun 27, 2017ANS Pharma's first study: phase 2 study in Diabetes ComplicationsNew to ANS PharmaANS Pharma · NCT03208309 · 40 enrolled · Brazil
  7. Sep 14, 2017Phase 2 study in Pemphigoid, BullousTWi Biotechnology · NCT03286582 · 10 enrolled · Taiwan
  8. Dec 19, 2017Phase 2 study in Epidermolysis BullosaCastle Creek Pharmaceuticals · NCT03389308 · 51 enrolled · United States
  9. Jan 30, 20182 phase 1 studies in HealthyCastle Creek Pharmaceuticals · NCT03472547, NCT03472534
  10. Mar 5, 20183 phase 1 studiesCastle Creek Pharmaceuticals · NCT03473197, NCT03473184, NCT03472287
  11. Mar 8, 2018Phase 2 study in Inherited Epidermolysis BullosaTWi Biotechnology · NCT03468322 · 9 enrolled · Taiwan
  12. Mar 16, 2020Phase 3 study in Osteoarthritis, KneeTRB Chemedica · NCT04318041 · 128 enrolled · Thailand
  13. Sep 12, 2023Phase 3 study in Epidermolysis Bullosa SimplexTWi Biotechnology · NCT06073132 · 80 enrolled · United States, Australia, Austria and more
  14. May 7, 2025Accro Bioscience (Suzhou)'s first study: phase 2 study in Plaque PsoriasisNew to Accro Bioscience (Suzhou)Accro Bioscience (Suzhou) · NCT06972888 · 145 enrolled · China

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Osteoarthritis, KneeTRB Chemedica · NCT04318041

TargetBeta

IL1B →read by rule
“AC-203 (diacerein 1% ointment) is a topical formulation of diacerein, well-known for its ability to inhibit IL-1β and other proinflammatory cytokines.”study text, by rule · the study

Other programs on IL1B

ProgramCompanyFurthest phaseStudies
lutikizumabAbbViephase 312
arumakimigNovartisphase 27
ABBV-1451AbbViephase 11

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06972888Plaque Psoriasis · China2CompletedAccro Bioscience (Suzhou)Mar 7, 2025145
NCT06073132Epidermolysis Bullosa Simplex · United States, Australia, Austria and more3Active, not recruitingTWi BiotechnologyJun 10, 202680
NCT04318041Osteoarthritis, Knee · Thailand3Active, not recruitingTRB ChemedicaDec 31, 2026128
NCT03472287Epidermolysis Bullosa · United States1CompletedCastle Creek PharmaceuticalsJan 31, 201911
NCT03468322Inherited Epidermolysis Bullosa · Taiwan2CompletedTWi BiotechnologyApr 9, 20199
NCT03473197Healthy · United States1CompletedCastle Creek PharmaceuticalsMar 9, 201861
NCT03473184Healthy · United States1CompletedCastle Creek PharmaceuticalsDec 15, 201734
NCT03472547Healthy · United States1CompletedCastle Creek PharmaceuticalsMar 3, 2018234
NCT03472534Healthy · United States1CompletedCastle Creek PharmaceuticalsJan 30, 201846
NCT03389308Epidermolysis Bullosa · United States2CompletedCastle Creek PharmaceuticalsApr 17, 202051
NCT03286582Pemphigoid, Bullous · Taiwan2TerminatedTWi BiotechnologyDec 25, 201810
NCT03208309Diabetes Complications · Brazil2CompletedANS PharmaAug 201540
NCT03154333Epidermolysis Bullosa Simplex · United States, Australia, Austria and more2TerminatedCastle Creek PharmaceuticalsOct 15, 201854
NCT02688400Osteoarthritis · Austria, Belgium, Canada and more3CompletedTRB Chemedica InternationalJun 26, 2018380
NCT02287818Gout · Taiwan2CompletedTWi BiotechnologyOct 27, 2016127
NCT01712204Hyperuricemia · Taiwan2CompletedTWi BiotechnologySep 201382
NCT01276106Diabetes Mellitus, Type 2 · United States, Taiwan2CompletedTWi BiotechnologyFeb 2012259
NCT01264211Arthritis, Rheumatoid · Thailand2CompletedTRB ChemedicaJun 201240
NCT00451360Osteoarthritis, Hip · France3CompletedWockhardt500
NCT00445276Osteoarthritis, Knee · France4CompletedWockhardtSep 2006500
NCT00440661Osteoarthritis · Canada4CompletedWockhardtOct 200896

How it is read

Names in the registry

  • “Diacerein”, 4 entries
  • “diacerein 1% ointment”, 4 entries
  • “AC-201”, 3 entries
  • “AC-203”, 2 entries
  • “Diacerein 1% ointment”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.